Business Context and Reporting Period
This Form 8-K Current Report for KALA BIO, Inc. (Nasdaq: KALA) was filed on December 16, 2025. The filing primarily announces the date of the Company's next Annual Meeting of Stockholders and provides updates regarding recent financing transactions and executive leadership changes involving investor David Lazar.
Key Financial Metrics and Capital Structure
The filing does not report standard operating financial metrics such as revenue, profit, cash flow, or margins. However, it discloses specific capital raising activities:
- Convertible Loan: On November 9, 2025, the Company entered into a Convertible Loan Agreement with David Lazar for $375,000.
- Private Placement (Series AA): On November 24, 2025, the Company closed the first tranche of a private placement, issuing 900,000 Series AA Preferred Shares at $2.00 per share, generating $1.8 million in gross proceeds.
- Private Placement (Series AAA): A second tranche for Series AAA Preferred Shares was agreed upon for up to $6.0 million in aggregate gross proceeds, though the closing for this tranche has not yet occurred.
Material Changes and Corporate Actions
Significant corporate governance and transactional changes have occurred since the last reporting period:
- Annual Meeting Date: The Board has set the next Annual Meeting for January 30, 2026. Due to this date being more than 30 days from the anniversary of the last meeting, the deadline for Rule 14a-8 stockholder proposals is December 27, 2025.
- Executive Leadership: David Lazar was appointed Chief Executive Officer and Principal Financial Officer effective immediately following the November 24, 2025 closing. He was also elected as a Class II Director and Chair of the Board.
- Transfer of Rights: Mr. Lazar has contracted to sell his rights to purchase the Series AAA Preferred Shares to an unaffiliated investor, AK Holdings Group Inc. (a Panamanian company), while retaining his Series AA holdings and the Convertible Loan.
- Strategic Consulting: On December 11, 2025, the Company engaged a principal of the Lazar Transferee as a consultant to assist in identifying and consummating a strategic alternative transaction.
Outlook, Risks, and Contingencies
The Company highlights several forward-looking risks and contingencies:
- Closing Conditions: The receipt of the remaining funds from the Series AAA Preferred Share closing is contingent upon satisfying conditions, including obtaining necessary Stockholder Approvals.
- Strategic Alternatives: The Company is actively seeking a strategic alternative transaction, but there is no guarantee such a transaction will be identified or consummated on the anticipated timeline.
- Listing Status: There is a risk regarding the Company's ability to maintain its listing on The Nasdaq Capital Market.
- Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ materially from expectations due to various uncertainties.
Investor Verification Checklist
- Verify the status of the Series AAA Preferred Share closing and whether Stockholder Approvals have been obtained.
- Confirm the details of the strategic alternative transaction being pursued with the assistance of the new consultant.
- Review the proxy statement for the January 30, 2026 Annual Meeting for specific matters to be voted on and the exact time/location.
- Monitor the Company's compliance with Nasdaq listing requirements given the recent capital structure changes.
- Check for any updates regarding the transfer of rights to AK Holdings Group Inc. and the finalization of that transaction.